

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10576824
Filing Date	2004-10-22
First Named Inventor	Phipps et al.
Art Unit	1617
Examiner Name	
Attorney Docket Number	176/61654

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6429226	B1	2006-08-06	STJERN SCHANTZ et al.	
	2	6399640	B1	2002-06-04	SAHOO et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10576824
	Filing Date	2004-10-22
	First Named Inventor	Phipps et al.
	Art Unit	1617
	Examiner Name	
	Attorney Docket Number	176/61654

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ANDRE et al., Platelet-Derived CD40L The Switch-Hitting Player of Cardiovascular Disease, Circulation, 2002, 896-899, Vol. 106, United States.	<input type="checkbox"/>
	2	MARX et al., Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease, Circulation, 2003, 1954-1957, Vol. 107, United States.	<input type="checkbox"/>
	3	ALAIMO et al., Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand, Circulation, 2002, 2849-2854, Vol. 105, United States.	<input type="checkbox"/>
	4	PRASAD et al., Soluble CD40 Ligand Induces Beta 3 Integrin Tyrosine Phosphorylation and Triggers Platelet Activation by Outside-In Signaling, PNAS, October 14, 2003, 12367-12371, Vol. 100:21, United States.	<input type="checkbox"/>
	5	SANGUIGNI et al., Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients, Circulation, 2005, 412-419, Vol. 111, United States.	<input type="checkbox"/>
	6	AKBIYIK et al., Human Bone Marrow Megakaryocytes and Platelets Express PPAR $\gamma$ , and PPAR $\gamma$ Agonists Blunt Platelet Release of CD40 Ligand and Thromboxanes, Blood, September 2004, 1361-1368, Vol. 104:5, United States.	<input type="checkbox"/>
	7	SMYTH et al., PPAR $\gamma$ Agonists: A new Strategy for Antithrombotic Therapy, J Thromb Haemost, 2005, 2147-2148, Vol. 3, United States.	<input type="checkbox"/>
	8	MORENO et al., The Year in Atherothrombosis, J Am Coll Cardiol, 2004, 2099-2110, Vol. 44, United States.	<input type="checkbox"/>
	9	CAPLUS Accession 2004:84523 for CUI et al., Protective Effects of PGE on Vascular Endothelial Function in Diabetic Atherosclerotic Rabbits, Tianjin Yiyao, 2002, 616-619, Vol. 30:10, China.	<input type="checkbox"/>
	10	MARX et al., Antidiabetic PPAR $\gamma$ -Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Persons with Coronary Artery Disease, Arterioscler. Thromb. Vasc. Biol., 2003, 283-288, Vol. 23, United States.	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number	10576824
	Filing Date	2004-10-22
	First Named Inventor	Phipps et al.
	Art Unit	1617
	Examiner Name	
	Attorney Docket Number	176/61654

	11	International Search Report, 2005-10-12.	<input type="checkbox"/>
--	----	------------------------------------------	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.